Northwest Biotherapeutics
- Company typePublic
- Founded1998
- HeadquartersBethesda, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Northwest Biotherapeutics firmographics
Firmographics- Name
- Northwest Biotherapeutics
- Legal name
- Northwest Biotherapeutics, Inc.
- Website
- https://nwbio.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Northwest Biotherapeutics industry classification
Industry- Product category
- Cancer Immunotherapy / Personalized Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Dendritic Cell & Other APC-based Therapies (HLAAABAF)
- akta.pro secondary industries
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)
Keywords
Where Northwest Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Northwest Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Others
Revenue model
- DCVax-L Commercialization: The company is pursuing regulatory approval (MAA to UK MHRA) for commercial sale of DCVax-L for glioblastoma. As a personalized cell therapy, each treatment would be manufactured for individual patients using their own cells and tumor tissue.
- DCVax-Direct and DCVax-Prostate Pipeline: Additional product candidates in clinical development for inoperable solid tumors and late-stage prostate cancer. Revenue would be generated upon successful regulatory approvals and commercialization.
- Leukapheresis Services: The company established its own dedicated leukapheresis clinic at The London Welbeck Hospital to provide leukapheresis services for other parties, potentially generating service revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Northwest Biotherapeutics product offering
Product offeringCore offering
Northwest Biotherapeutics develops and is working to commercialize personalized dendritic cell-based cancer vaccines using its proprietary DCVax platform technology. The company's lead product candidate, DCVax-L, is in late-stage review for glioblastoma brain cancer with the UK MHRA, and additional pipeline candidates (DCVax-Direct, DCVax-Prostate) target inoperable solid tumors and late-stage prostate cancer respectively. The company also operates dedicated manufacturing infrastructure in the UK and a leukapheresis clinic to support scale-up of its immunotherapy programs.
Product overview
Northwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines based on its DCVax® dendritic cell-based platform technology. The company has a portfolio of product candidates: DCVax-L (for glioblastoma brain cancer, Phase III completed), DCVax-Direct (for inoperable solid tumor cancers, Phase I/II), and DCVax-Prostate (for late-stage prostate cancer, Phase III cleared). All DCVax products are made from the patient's own dendritic cells, which are matured and activated using proprietary processes, then combined with tumor-specific antigens to mobilize the entire immune system against cancer. The company has also acquired Flaskworks automation technology for scalable manufacturing and Advent BioServices for integrated manufacturing operations.
Differentiator
Problem solved
Functional benefit
Brands
- DCVax: Platform technology using activated dendritic cells to develop personalized cancer vaccines, including DCVax-L, DCVax-Direct, and DCVax-Prostate product lines
Products and services
- DCVax-L
Quantifiable outcome
- 80% of patients achieved clinical benefits (longer delay in disease progression and longer extension of survival) in clinical trials to date
- +2 more outcomes
Companies that use Northwest Biotherapeutics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Northwest Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Northwest Biotherapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and strategic.
- Advent BioServices Ltd.coreAcquisition completed making Advent BioServices a wholly owned subsidiary. Advent is a UK-based contract development and manufacturing organization (CDMO) that had been partnering with the company. The acquisition aims to improve operational efficiency and scale up manufacturing capacity, streamline manufacturing, supply chain, and operational efficiencies.
- Roswell Park Comprehensive Cancer CentercoreExclusive license for portfolio of dendritic cell technologies and intellectual property including 5 patent families filed in 2023. Technologies include enhanced dendritic cells, DC-based therapies, conditioning regimens, and approaches to reprogram tumor microenvironment. License terms include upfront fee, milestones up to $2.3 million, and 4% royalties on product sales.
- Cognate BioServices, Inc.strategicSettlement agreement resolving past matters and providing for restart of DCVax-Direct production. Previously partnered on manufacturing of cell therapy products. New DCVax-Direct manufacturing agreement established.
- King's Health Partners (King's College Hospital and King's College London)strategicPartnership to manufacture and deliver DCVax-L treatment for brain cancer patients as part of ongoing clinical trial for Glioblastoma multiforme in Europe. Includes both clinical trial and compassionate use programs.
- Fraunhofer Institute for Cell Therapy and Immunology (IZI)strategicPartnership for production of DCVax-L for brain cancer for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe with over 18,000 staff. Received $5.5 million German government grant for manufacturing and brain cancer trial at 30 sites in Germany.
- Dr. Annalisa JenkinsstrategicStrategic Adviser appointed to support development and expansion of DCVax dendritic cell-based cancer vaccine platform. Dr. Jenkins has over 25 years of biopharma leadership experience including CEO of Dimension Therapeutics and senior roles at Merck Serono and Bristol-Myers Squibb. Awarded Order of the British Empire (OBE).
- Dr. Linda LiaustrategicJoined the company's Scientific Advisory Board. Previously served as Principal Investigator of the Phase 3 trial of DCVax-L for treatment of glioblastoma. Currently Chair of the Department of Neurosurgery at UCLA.
- Dr. Pawel KalinskicoreLead scientist-clinician from Roswell Park collaboration. Company plans to collaborate with Dr. Kalinski on further development of licensed dendritic cell technologies. Dr. Kalinski is one of the foremost experts on dendritic cell biology and therapies.
Scale indicators9 records
Recent moves8 records
Expansion highlights7 records
Northwest Biotherapeutics competitors and assessment
Company assessmentEmerging players
- Cellectis: Cellectis develops allogeneic CAR-T cell therapies for oncology. Comparable as a cell therapy platform pursuing hematologic and solid tumor indications with novel gene editing approaches.
- Inovio Pharmaceuticals: Inovio develops DNA-based cancer vaccines and immunotherapies for HPV-related cancers and other solid tumors. Comparable as an emerging cancer vaccine platform targeting similar indications.
Direct peers
- Dendreon: Dendreon's Provenge (sipuleucel-T) is the only commercially approved autologous dendritic cell therapy for cancer (prostate). Like NW Bio, Dendreon pioneered personalized DC-based cancer vaccines and serves as the most direct commercial precedent for DCVax-L.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, including Tecelra. Comparable in autologous cell therapy targeting solid tumors with personalized manufacturing.
- Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Comparable as a cell therapy company pursuing multiple hematologic and solid tumor indications with platform-based development.
- Iovance Biotherapeutics: Iovance develops autologous cell therapies for solid tumors (TIL therapy, with FDA-approved Amtagvi for melanoma). Comparable in autologous cell therapy manufacturing complexity, regulatory pathway, and addressable solid tumor indications.
Broad incumbents
- Moderna: Moderna is developing mRNA-based personalized cancer vaccines (mRNA-4157) in combination with checkpoint inhibitors. Competes in the personalized cancer vaccine space with far greater resources and pipeline scale.
- BioNTech: BioNTech is a leading cancer immunotherapy company developing individualized mRNA cancer vaccines (BNT122) and other immune-targeted therapies. Overlaps with DCVax-L in the personalized cancer immunotherapy space, particularly for solid tumors.
- Bavarian Nordic: Bavarian Nordic develops therapeutic cancer vaccines (e.g., CV301, Prostvac) and is a broader oncology immunotherapy incumbent. Overlaps with DCVax in cancer vaccine positioning for solid tumors.
- Bristol-Myers Squibb: BMS owns cell therapy assets through Juno and Celgene (e.g., Breyanzi, Abecma) and the immuno-oncology franchise Opdivo. Broad incumbent competing in oncology cell therapy and immune checkpoint space relevant to DCVax combinations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Northwest Biotherapeutics social profiles
Digital presenceNorthwest Biotherapeutics compliance and trust
Trust signalCompliance2 records
Northwest Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Northwest Biotherapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Northwest Biotherapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Northwest Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Northwest Biotherapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Northwest Biotherapeutics
What does Northwest Biotherapeutics do?
Northwest Biotherapeutics develops and is working to commercialize personalized dendritic cell-based cancer vaccines using its proprietary DCVax platform technology. The company's lead product candidate, DCVax-L, is in late-stage review for glioblastoma brain cancer with the UK MHRA, and additional pipeline candidates (DCVax-Direct, DCVax-Prostate) target inoperable solid tumors and late-stage prostate cancer respectively. The company also operates dedicated manufacturing infrastructure in the UK and a leukapheresis clinic to support scale-up of its immunotherapy programs.
Is Northwest Biotherapeutics a public or private company?
Northwest Biotherapeutics is a public company. It is classified as public and is currently operating.
When was Northwest Biotherapeutics founded?
Northwest Biotherapeutics was founded in 1998. It employs 11 to 50 people.
Where is Northwest Biotherapeutics based?
Northwest Biotherapeutics is headquartered in Bethesda, United States, in the North America region.
How does Northwest Biotherapeutics make money?
Three revenue lines are on record. DCVax-L Commercialization is the primary driver. The others are DCVax-Direct and DCVax-Prostate Pipeline and leukapheresis Services.
Who are Northwest Biotherapeutics's main competitors?
Emerging players on record are Cellectis and Inovio Pharmaceuticals. Direct peers are Dendreon, Adaptimmune Therapeutics, Fate Therapeutics and Iovance Biotherapeutics. Broad incumbents are Moderna, BioNTech, Bavarian Nordic and Bristol-Myers Squibb.
Does Northwest Biotherapeutics have an API?
No public API is recorded for Northwest Biotherapeutics.
What industry is Northwest Biotherapeutics in?
Northwest Biotherapeutics's product category is Cancer Immunotherapy / Personalized Cell Therapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.